Declining prevalence of HIV-1 drug resistance in antiretroviral treatment-exposed individuals in Western Europe
De Luca, Andrea × Dunn, David Zazzi, Maurizio Camacho, Ricardo Torti, Carlo Fanti, Iuri Kaiser, Rolf Sönnerborg, Anders Codoñer, Francisco M Van Laethem, Kristel Vandamme, Anne-Mieke Bansi, Loveleen Ghisetti, Valeria van de Vijver, David A M C Asboe, David Prosperi, Mattia C F Di Giambenedetto, Simona for the SEHERE collaboration in Chain #
Published by the University of Chicago Press for the Infectious Diseases Society of America
The Journal of infectious diseases vol:207 issue:8 pages:1216-1220
HIV-1 drug resistance represents a major obstacle to infection and disease control. This retrospective study analyzes trends and determinants of resistance in antiretroviral treatment (ART)-exposed individuals across 7 countries in Europe. Of 20 323 cases, 80% carried at least one resistance mutation: these declined from 81% in 1997 to 71% in 2008. Predicted extensive 3-class resistance was rare (3.2% considering the cumulative genotype) and peaked at 4.5% in 2005, decreasing thereafter. The proportion of cases exhausting available drug options dropped from 32% in 2000 to 1% in 2008. Reduced risk of resistance over calendar years was confirmed by multivariable analysis.